EVERGREEN Study Evaluates Everolimus After Progression in Advanced ER-Positive, HER2-Negative Breast Cancer

Everolimus Offers Only a Modest Extra Brake on Advanced Breast Cancer After CDK4/6 Resistance

For patients with estrogen receptor-positive, HER2-negative advanced breast cancer, the moment a tumor progresses on a CDK4/6 inhibitor can feel like a therapeutic cliff. These drugs, including palbociclib, ribociclib and abemaciclib, have transformed first-line treatment by slowing the cell cycle and delaying chemotherapy for many patients. But resistance is common, and the best strategy after progression remains uncertain. Now, an international real-world study suggests that adding the targeted drug everolimus to endocrine therapy may hold the disease at bay for slightly longer than endocrine therapy alone—but the gain is small, and toxicity means the treatment is unlikely to suit everyone.

The study, called EVERGREEN, analyzed outcomes for 207 women whose estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer had progressed after treatment with a CDK4/6 inhibitor. Of these patients, 150 received everolimus alongside endocrine therapy, while 57 received endocrine therapy without everolimus. After a median follow-up of 31.8 months, the median real-world progression-free survival was 5.0 months in the everolimus group, compared with 4.3 months among those given endocrine therapy alone. The adjusted hazard ratio for progression or death was 0.68, with a 95 percent confidence interval of 0.47 to 0.99.

That result means the everolimus-containing treatment was associated with an approximately 32 percent lower relative risk of progression or death during the study period after statistical adjustment. It does not mean that every patient gained a fixed additional 32 percent of survival, nor that the cancer was controlled for 32 percent longer. The absolute difference in median progression-free survival was only 0.7 months—roughly three weeks. The researchers therefore describe the benefit as modest. There was no statistically significant improvement in the time until chemotherapy was needed or in overall survival, the measure that most directly captures whether treatment helps patients live longer.

Everolimus attacks a different part of the machinery that cancer cells use to grow. It inhibits mammalian target of rapamycin, or mTOR, a central signaling protein that helps regulate protein production, cell growth, metabolism and survival. In hormone receptor-positive breast cancer, signaling through the estrogen receptor can cooperate with the PI3K–AKT–mTOR pathway to keep malignant cells dividing even when estrogen-driven growth is being suppressed. Laboratory studies have suggested that increased activity in this pathway can contribute to resistance against CDK4/6 inhibition. By blocking mTOR while continuing endocrine therapy, clinicians aim to shut down a bypass route that cancer cells may exploit after cell-cycle treatment stops working.

The biological rationale, however, does not guarantee a large clinical effect. Tumors that acquire resistance to CDK4/6 inhibitors are not uniform. Some develop alterations in genes such as ESR1, which encodes the estrogen receptor; others involve the PI3K–AKT–mTOR network, including PIK3CA, AKT1 or PTEN. Still others may become less dependent on estrogen signaling altogether, switch to alternative growth programs or contain several resistant subclones at once. Everolimus may be most useful when the mTOR pathway remains an important engine of tumor growth, but the EVERGREEN study did not establish a biomarker that could reliably identify such patients before treatment.

The study’s design is important for interpreting its findings. EVERGREEN was a multicentre, international, retrospective quasi-experimental study rather than a randomized clinical trial. The investigators compared women treated at centers where everolimus plus endocrine therapy was the standard approach with women treated at centers where endocrine therapy alone was standard. This approach can provide valuable evidence from routine oncology practice, especially when randomized trials have not answered a specific treatment question. It also introduces potential sources of bias: treatment policies differ between hospitals, physicians may select everolimus for particular types of patients, and medical records may not capture every factor influencing treatment choice or disease assessment.

The patient groups were broadly balanced at baseline, according to the researchers, but the everolimus cohort had received a greater number of previous lines of therapy. That imbalance matters because heavily pretreated disease can be more biologically resistant and patients may have poorer overall health or fewer remaining treatment options. The investigators used adjusted analyses to account for measured differences, but statistical methods cannot completely remove the effects of unknown or unrecorded factors. “Real-world progression-free survival” is also less tightly controlled than progression-free survival in a prospective trial, where imaging schedules, response assessments and follow-up procedures are standardized.

The safety findings were consistent with earlier reports of everolimus, but the abstract does not provide a detailed breakdown of adverse events. The drug can cause mouth inflammation, rash, fatigue, diarrhea, metabolic changes and suppression of blood-cell production; it can also produce noninfectious pneumonitis, an inflammatory lung complication. These risks are particularly relevant in advanced cancer, where maintaining quality of life is a central treatment goal. A therapy that delays progression by several weeks may be worthwhile for a carefully selected patient who wants to remain on oral treatment and has limited alternatives, but less attractive for someone vulnerable to complications or eligible for a better-matched molecular therapy.

The findings arrive in a rapidly changing treatment landscape. After CDK4/6 inhibitor progression, options may include endocrine drugs designed to target specific resistance mutations, inhibitors of PI3K or AKT signaling, antibody–drug conjugates and chemotherapy. For example, the presence of an ESR1 mutation or an alteration in PIK3CA, AKT1 or PTEN may influence the suitability of other targeted approaches, although the best sequence of therapies is still evolving. The EVERGREEN results do not show that everolimus should replace these options. Instead, they suggest that it remains a possible strategy for a subset of patients whose disease is still endocrine-sensitive and for whom the expected benefits outweigh the drug’s side effects.

The study also illustrates why treatment after CDK4/6 resistance cannot be reduced to a single universal prescription. A median benefit measured in weeks can conceal meaningful differences between individuals: some patients may experience little response, while others may achieve substantially longer disease control. Future trials will need to connect outcomes to tumor biology, circulating tumor DNA, prior endocrine exposure and the pattern of progression. For now, EVERGREEN provides a cautiously encouraging but not practice-revolutionizing message: everolimus can add a small amount of control after CDK4/6 inhibitors, but the decision to use it should be individualized rather than automatic.